Effect of early application of tirofiban on platelet function in patients with coronary heart disease after PCI
Wu Jiafeng
Meng Juan
Wu Qiang
Abstract：Objective To investigate the effect of early tirofiban on platelet function in patients with coronary artery disease after percutaneous coronary intervention (PCI). Methods 78 patients with coronary heart disease who underwent PCI were enrolled from February 2016 to March 2017. They were randomly divided into tirofiban group and non-tirofiban group. The patients in the two groups were treated with clopidogrel tablets and aspirin enteric-coated tablets. The patients were treated with intravenous infusion of 10 μg/kg tirofiban and 0.5 μg/kg/min after PCI. Differences in platelet function between the two groups before and after treatment were compared. Results Before PCI, the platelet adhesion rate, platelet aggregation rate, maximal aggregation time and P-selectin concentration were not significantly different between the tirofiban group and the control group (P>0.05). After PCI, those above in tirofiban group were lower than those in control group (P<0.05). And there was no statistical significance of the incidence of bleeding complications between two groups (17.1% vs. 16.2%, P>0.05). The incidence of slow thrombosis, no-reflow and re-occlusion in the treatment group was significantly lower than those in the control group (P<0.05), but there was no statistical significance of the incidence of recurrent angina between two groups (5.4% vs. 17.1%, P>0.05). Conclusion Early bolus tirofiban can effectively inhibit the platelet function of PCI patients, and it is safer.
Keywords：TirofibanInterventional therapyCoronary heart diseasePlatelet function
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 107-109 )